Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kathy Flanagan

Psychiatry Houston, TX Medical Doctor

NPI 1073662714 CMS profile 3055

2211 Norfolk St, Suite 505, Houston, TX 77098

Open in the dashboard

General payments

$443,470

846 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kathy Flanagan of Houston, TX is reported in the CMS Open Payments database as having received $443,470 across 846 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $92,923 127
2024 General $5,710 15
2023 General $586 15
2022 General $9,920 23
2021 General $115,303 197
2020 General $63,515 107
2019 General $155,513 362

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kathy Flanagan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Kathy Flanagan were reported at $92,923. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Kathy Flanagan Psychiatry median Middle half National median
2019 $155,513 $184 $59–$605 $163
2020 $63,515 $119 $36–$372 $114
2021 $115,303 $143 $43–$576 $132
2022 $9,920 $153 $50–$590 $149
2023 $586 $170 $56–$651 $160
2024 $5,710 $179 $57–$673 $164
2025 $92,923 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Allergan Inc. $228,502 459 payments
  2. AbbVie, Inc. $206,679 338 payments
  3. Vanda Pharmaceuticals Inc. $5,042 4 payments
  4. Teva Pharmaceuticals USA, Inc. $518 9 payments
  5. GlaxoSmithKline, LLC. $345 4 payments
  6. Inspire Medical Systems, Inc. $277 3 payments
  7. Janssen Pharmaceuticals, Inc $238 2 payments
  8. Neurocrine Biosciences, Inc. $234 2 payments
  9. Alexion Pharmaceuticals, Inc. $216 2 payments
  10. Novo Nordisk Inc $192 2 payments
  11. Other $1,227 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $352,210 177 payments
  2. Travel and Lodging $71,847 306 payments
  3. Food and Beverage $14,765 358 payments
  4. Consulting Fee $4,500 1 payment
  5. Education $148 4 payments
Products named General payments · program years 2019–2025
  1. VRAYLAR Neuroscience $310,211 570 payments
  2. VRAYLAR Neuroscience $124,930 226 payments
  3. FANAPT $5,042 4 payments
  4. XARELTO $358 3 payments
  5. BENLYSTA $345 4 payments
  6. AUSTEDO $301 6 payments
  7. INSPIRE $277 3 payments
  8. Austedo XR $146 2 payments
  9. INGREZZA $125 1 payment
  10. AMPLATZER $122 1 payment
  11. Other $807 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

102

Median for Psychiatry & Neurology: 100

Drug cost

$5,545

Median for Psychiatry & Neurology: $2,986

Branded share of claims

10.8%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vilazodone Hcl Generic 15 $2,653
Dexmethylphenidate Hcl Er Dexmethylphenidate Hcl Brand 11 $1,893
Escitalopram Oxalate Generic 28 $422
Aripiprazole Generic 16 $306
Lamotrigine Generic 14 $191
Alprazolam Generic 18 $81

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FANAPT
  • Vanda Pharmaceuticals Inc. $5,042
$5,042 — —
VRAYLAR
  • AbbVie, Inc. $144
$144 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

846 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record